Bridgeway Capital Management’s Corcept Therapeutics CORT Stock Holding History

Bridgeway Capital Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-19,000	Closed	-$374K	–	1274
2021 Q3	$374K	Hold	19,000	–	–	0.01%	1116
2021 Q2	$418K	Buy	19,000 +3,200	+20%	+$71.2K	0.01%	1117
2021 Q1	$376K	Hold	15,800	–	–	0.01%	1178
2020 Q4	$413K	Sell	15,800 -1,600	-9%	-$33.7K	0.01%	1017
2020 Q3	$303K	Buy	+17,400	New	+$277K	0.01%	1064
2019 Q2	–	Sell	-45,600	Closed	-$535K	–	1332
2019 Q1	$535K	Sell	45,600 -15,800	-26%	-$196K	0.01%	1007
2018 Q4	$820K	Buy	61,400 +30,400	+98%	+$402K	0.01%	809
2018 Q3	$435K	Hold	31,000	–	–	﹤0.01%	1178
2018 Q2	$487K	Hold	31,000	–	–	﹤0.01%	1139
2018 Q1	$510K	Sell	31,000 -5,300	-15%	-$98.2K	0.01%	1089
2017 Q4	$656K	Sell	36,300 -1,500	-4%	-$27.2K	0.01%	1004
2017 Q3	$730K	Sell	37,800 -13,900	-27%	-$207K	0.01%	962
2017 Q2	$610K	Hold	51,700	–	–	0.01%	1027
2017 Q1	$567K	Hold	51,700	–	–	0.01%	1031
2016 Q4	$375K	Buy	+51,700	New	+$405K	﹤0.01%	1175

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bridgeway Capital Management's CORT Position: Q4 2021 in Review

Bridgeway Capital Management sold out of Corcept Therapeutics (CORT) in Q4 2021, closing a stake of 19,000 shares — an estimated $374K sold.

Bridgeway Capital Management first reported a position in CORT in Q4 2016 and held it in 15 quarters. The position peaked at $820K in Q4 2018. 208 funds tracked by Wall St. Rank hold CORT as of Q4 2021.

Bridgeway Capital Management reported no remaining Corcept Therapeutics position as of Q4 2021 after selling out during the quarter.
Bridgeway Capital Management sold 19,000 Corcept Therapeutics shares in Q4 2021, an estimated $374K.
Bridgeway Capital Management first reported a position in Corcept Therapeutics in Q4 2016 and held it in 15 quarters.
Bridgeway Capital Management's Corcept Therapeutics position peaked at $820K in Q4 2018.
208 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2021.

Based on Bridgeway Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.